Selective COX-2 inhibitors does not depend on the role of COX-2 anti-cancer.docVIP

 PAGE \* MERGEFORMAT 28 Selective COX-2 inhibitors does not depend on the role of COX-2 anti-cancer Abstract non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit tumor occurrence and development, one of the mechanism is inhibition of cyclooxygenase -2 (COX-2) activity. COX-2 in a variety of high expression in both tumor tissue, thereby promoting tumor cell proliferation and inhibiting apoptosis. However, COX-2 inhibitors, there is still is not dependent on COX-2 anti-cancer effect. In this review, we will elaborate on COX-2 inhibitors, COX-2 does not depend on the molecular target, and discuss how these targets are to play anti-cancer effect. Keywords: COX-2 inhibitors; cancer In recent years, selective cyclooxygenase -2 (COX-2) inhibitors, anti-cancer role of a research focus of concern. Since celecoxib in 1998, rofecoxib in 1999 entered the pharmaceutical market has been more than 3000 studies have shown that the molecular target of these drugs and clinical effectiveness. However, due to the long-term use of COX-2 inhibitors may increase the risk of cardiovascular disease risk, making these drugs is facing a severe test. Bextra and other C0X-2 inhibitors are FDA ordered recovery, current research focused on celecoxib and rofecoxib on. In vitro tests have shown the majority of celecoxib and rofecoxib inhibit tumor concentration than the activity of COX-2 inhibition required high concentrations, indicating there is still is not dependent on COX-2 anti-cancer mechanism, but also in the treatment of cancer has an important role. This article focuses on COX-2 inhibitors (primarily celecoxib and rofecoxib) is not dependent on COX-2 anti-cancer mechanism of action. In general, COX-2 inhibitor anti-cancer mechanism of action, including inhibition of cell cycle progression and induce apoptosis and inhibit angiogenesis and metastasis of three parts. An inhibition of cell cycle progression Cell cycle phase shift betw